Diabetes Reference Library

Clinical Studies

SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes

Wheeler D, James J, Patel D et al. As part of the Improving Diabates Steering Committee
Diabetes Therapy 2020; 11, 2757-2774

Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people

Khunti K, Wolden ML, Thorsted BL, et al
Diabetes Care 2013;36(11):3411–7

Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes

Paul SK, et al
Cardiovascular Diabetol 2015;14:100-10

Effects of intensive glucose lowering in type 2 diabetes

ACCORD Study Group
N Engl J Med 2008;358:2545–59

Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes

Zaccardi F, et al
Diabetes Obes Metab 2016;18(8):738-94

Factors associated with clinical inertia: an integrative review

Aujoulat I, Jacquemin P, Rietzscel E, et al
Adv Med Educ Pract 2014;5:141–7

Sustained effect of intensive treatment of diabetes mellitus on development and progression of diabetic nephropathy

Epidemiology of Diabetes Interventions and Complications Study (EDIC) Group.
JAMA 2003;290(16):2159–67

The kidney as a treatment target for type 2 diabetes

Dokken E
Diabetes Spectrum 2012;25(1):29-36

UKPDS and the Legacy Effect

Chalmers J et al
N Engl J Med 2008;359:1618–20

10-year follow-up of intensive glucose control in type 2 diabetes

Holman RR, Paul SK, Bethel MA, et al
N Engl J Med 2008;359:1577–1589

Clinical update: The important role of dual kidney function testing (ACR and eGFR) in primary care: Identification of risk and management in type 2 diabetes

Seidu S, Barrat J, Khunti K
Primary Care Diabates 2020;14(4):370-375

SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice

Wilding J, Fernando K, Milne K et al
Diabetes Therapy 2018; 9:1757-1773

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice

Ali A, Bain S, Hicks D et al
Diabates Therapy 2019; 10:1595-1622

Resources

Assessing fitness to drive: a guide for medical professionals

DVLA

Facts and Stats, 2016

Diabetes UK

National Diabetes Audit 2016-17

NHS Digital

New diagnostic criteria for diabetes (Jan 2011) – Use of haemoglobin A1c (HbA1c) in the diagnosis of diabetes mellitus in the UK

Diabetes UK

Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus

WHO

Guidelines and clinical standards

American Diabetes Association. Standards of Medical Care in Diabetes–2019. Abridged for primary care providers. American Diabetes Association.

ADA
Clinical Diabetes 2019 Jan; 37(1):11-34

NG136. Hypertension in adults (2019). Diagnosis and management

NICE

CG182. Chronic kidney disease in adults: assessment and management (2014)

NICE

Diabetes in adults (QS6)

NICE

KDIGO Diabetes and CKD, Scope of work, 2018.

KIDGO

Management of Hyperglycemia in Type 2 Diabetes, 2018

ADA/EASD

NICE Pathways. Type 2 diabetes in adults, 2019

NICE

Pharmacological management of glycaemic control in people with Type 2 Diabetes

SIGN 154

2019/20 General Medical Services (GMS) contract: Quality and Outcomes Framework (QOF), April 2019

BMA/NHS England

American Diabetes Association and the European Association for the Study of Diabetes, Consensus report, 2019

ADA/EASD

PATIENT RESOURCES